Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC)
-
- Jassem
- Creator
Journal
-
- J Clin Oncol
-
J Clin Oncol 28 (suppl), 2010